Calyxt (NASDAQ:CLXT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. It researches and develops seeds and food ingredients for agricultural, feed, and food applications as well as offers fat saturation and gluten reduction in soybean oil and wheat. Calyxt, Inc. is based in New Brighton, United States. “

Several other equities research analysts also recently issued reports on CLXT. Citigroup decreased their price objective on shares of Calyxt from $19.00 to $13.00 and set a “neutral” rating for the company in a research note on Monday, November 19th. Jefferies Financial Group reiterated a “buy” rating and set a $27.00 price objective on shares of Calyxt in a research note on Thursday, November 15th. Finally, Goldman Sachs Group assumed coverage on shares of Calyxt in a research note on Friday, September 7th. They set a “neutral” rating and a $18.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $21.05.

CLXT traded down $0.37 during trading on Wednesday, hitting $11.07. 35,583 shares of the company’s stock were exchanged, compared to its average volume of 65,997. The company has a quick ratio of 15.01, a current ratio of 15.01 and a debt-to-equity ratio of 0.17. Calyxt has a 1 year low of $11.07 and a 1 year high of $27.23. The company has a market cap of $375.23 million, a P/E ratio of -9.88 and a beta of 3.34.

Calyxt (NASDAQ:CLXT) last released its quarterly earnings data on Wednesday, November 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.06. Calyxt had a negative net margin of 6,256.67% and a negative return on equity of 33.08%. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.50 million. Research analysts anticipate that Calyxt will post -0.93 earnings per share for the current year.

In other Calyxt news, insider Daniel F. Voytas sold 4,666 shares of the business’s stock in a transaction that occurred on Thursday, September 20th. The shares were sold at an average price of $16.00, for a total transaction of $74,656.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Manoj Sahoo sold 2,521 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $14.84, for a total transaction of $37,411.64. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 20,553 shares of company stock valued at $303,275. 2.80% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC lifted its position in shares of Calyxt by 134.9% during the second quarter. Tower Research Capital LLC TRC now owns 6,583 shares of the company’s stock worth $123,000 after purchasing an additional 3,781 shares in the last quarter. PNC Financial Services Group Inc. acquired a new position in shares of Calyxt during the second quarter worth $186,000. California Public Employees Retirement System acquired a new position in shares of Calyxt during the second quarter worth $187,000. Granite Investment Partners LLC acquired a new position in shares of Calyxt during the second quarter worth $216,000. Finally, Essex Investment Management Co. LLC acquired a new position in shares of Calyxt during the third quarter worth $309,000. 28.30% of the stock is currently owned by institutional investors and hedge funds.

About Calyxt

Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for plants in the United States. It engages in the development of high oleic soybeans, high fiber wheat, herbicide tolerant wheat, powdery mildew resistant wheat, improved oil composition canola, herbicide tolerant canola, improved quality alfalfa and herbicide tolerant alfalfa, late blight resistant potatoes, cold storable/reduced browning potatoes, improved protein composition soybeans, drought tolerant soybeans, herbicide tolerant soybeans, and improved yield soybeans.

Featured Article: Conference Calls

Get a free copy of the Zacks research report on Calyxt (CLXT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.